A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement - 20/11/24
, Michael Bukhalo, MD b, Linda Stein Gold, MD c, Brad Glick, DO, MPH d, Mar Llamas-Velasco, MD e, Samuel Sanchez-Rivera, MD f, Anqi Pan, PhD g, Tianyu Zhan, PhD g, Leonidas Drogaris, MD g, Kevin Douglas, MD g, Greg St. John, PhD g, Ramon Espaillat, MD g, Robert Bissonnette, MD hAbstract |
Background |
In plaque psoriasis, palmoplantar areas are more difficult to treat.
Objective |
Evaluate the safety and efficacy of risankizumab (RZB) versus placebo (PBO) for the treatment of palmoplantar psoriasis.
Methods |
Patients were randomized to RZB or PBO for 16 weeks followed by RZB through week 52. The primary and secondary end points were achievement of palmoplantar Investigator's Global Assessment of “clear” or “almost clear” with ≥2-point reduction from baseline (ppIGA 0/1), achievement of ≥75%, ≥90%, and 100% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 75, PPASI 90, PPASI 100) and achievement of static Physician Global Assessment of “clear” or “almost clear” with ≥2-point reduction from baseline (sPGA 0/1) at week 16. Safety was based on treatment-emergent adverse events.
Results |
RZB demonstrated significant efficacy compared to PBO at week 16 in the patients achieving ppIGA 0/1 (33.3% vs 16.1% [P = .006]), PPASI 75 (42.5% vs 14.9% [P < .001]), PPASI 90 (27.6% vs 5.7% [P < .001]), sPGA 0/1 (32.2% vs 11.5% [P < .001]), and PPASI 100 (17.2% vs 1.1% [P < .001]). Results improved through week 52 with no new safety signals.
Limitation |
No biologic comparator.
Conclusions |
RZB demonstrated good tolerance and efficacy in palmoplantar psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : clinical trial, palmoplantar psoriasis, risankizumab
Abbreviations used : BSA, IL, PBO, PBO/RZB, PPASI, ppIGA, PPPsO, PsO, RZB, RZB/RZB, SAE, sPGA, TEAE
Plan
| Funding sources: AbbVie sponsored the study (NCT04713592) contributed to its design, collection, analysis, and interpretation of the data, and participated in the writing, review, and approval of the manuscript. |
|
| Statement on prior presentation: The results from IMMprint were presented at the fourth Annual Elevate-Derm PA & NP Conference: J Clin Aesthet Dermatol. 2024;17(1-2 Suppl 1):S15-S30. |
|
| IRB approval status: Approvals were obtained from local ethics committees, and the patients provided written informed consent. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki. |
Vol 91 - N° 6
P. 1150-1157 - décembre 2024 Retour au numéro
Article précédent
- JAAD Game Changers: Can pretreatment serum calcium level predict the efficacy of methotrexate in the treatment of severe plaque psoriasis?
- Jane M. Grant-Kels
- Factors associated with residual tumor at time of Mohs micrographic surgery for basal cell and squamous cell carcinomas
- Katherine G. Thompson, Raghav Tripathi, Jaroslaw Jedrych, Kristin P. Bibee, Jeffrey F. Scott, Elise Ng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?